

**Table S1. Unadjusted and adjusted NMSC recurrence rates five years after each treatment**

Treatment group	Recurrence rate [95% Confidence Interval] five years after treatment								
	UNIVERSITY SITE (30 recurrences in 857 tumors)			VA (23 recurrences in 631 tumors)			ENTIRE SAMPLE (53 recurrences in 1488 tumors)		
	Number of recurrences /number of tumors at baseline	Unadjusted 5-year recurrence rate	Adjusted 5-year recurrence rate <sup>a</sup>	Number of recurrences /number of tumors at baseline	Unadjusted 5-year recurrence rate	Adjusted 5-year recurrence rate <sup>a</sup>	Number of recurrences /number of tumors at baseline	Unadjusted 5-year recurrence rate	Adjusted 5-year recurrence rate <sup>a</sup>
Destruction	14 / 229	6.2% [2.5, 9.6]	4.3% [0.9, 7.6]	3 / 132	2.8% [0, 6.0]	2.7% [0, 5.8]	17 / 361	4.9% [2.3, 7.4]	3.8%[1.4, 6.1]
Excision	8 / 247	2.6% [0.3, 4.9]	2.6% [0.2, 4.8]	14 / 324	4.2% [1.7, 6.6]	3.8%[1.4, 6.2]	22 / 571	3.5% [1.8, 5.2]	3.3%[1.6, 4.9]
Mohs surgery	8 / 381	1.9% [0.2, 3.5]	1.8% [0.1, 3.5]	6 / 175	2.4% [0, 5.1]	1.4% [0, 3.2]	14 / 556	2.1% [0.6, 3.5]	1.7%[0.4, 3.0]

<sup>a</sup> All models adjusted for history of HIV, multiple NMSCs at presentation, tumor type (BCC or SCC), whether the tumor was histopathologically superficial or *in situ*, tumor in H-zone of the face, > 2 annual visits to dermatology, and in the entire sample, clinical site